Why the Airway Collapses During Sleep

Sleep apnea treatment has a credibility problem. CPAP — continuous positive airway pressure — is the gold standard. It works extraordinarily well when worn. The problem is that about half the people prescribed CPAP don’t use it consistently, and a significant proportion abandon it entirely within the first year. The machine is loud, the mask leaks, the straps leave marks on the face, the tube tangles, and waking up with a fighter pilot apparatus strapped to the head isn’t exactly romantic.

Enter oral appliance therapy: a custom-fitted dental device that repositions the jaw and tongue during sleep to prevent airway collapse. No electricity. No mask. No hose. The size of a sports mouthguard. And for millions of people with mild-to-moderate sleep apnea — and for the CPAP intolerant — the evidence shows it’s a legitimate, clinically meaningful alternative.

But there’s far more to understand here than the choice between a machine and a mouthguard. Sleep apnea is a cardiovascular disease. It’s a metabolic disease. It’s a brain health disease. The airway collapse is the mechanism, but the downstream consequences — when the problem goes untreated or undertreated — span virtually every organ system. This article covers the full picture: why the airway collapses, what happens to the body when it does, what the evidence actually shows for different treatment options, and how to build a management strategy that actually gets followed for the long term.

Why the Airway Collapses During Sleep

Obstructive sleep apnea (OSA) occurs when the pharyngeal airway — the soft tissue passage behind the tongue and below the palate — collapses repeatedly during sleep, causing momentary interruptions in breathing. Each event lasts 10 seconds to several minutes. The Apnea-Hypopnea Index (AHI) counts these events per hour: under 5 is normal, 5-14 is mild, 15-29 is moderate, 30+ is severe. But the AHI number alone tells an incomplete story — the oxygen desaturations, the arousal burden, and the sleep architecture fragmentation that accompany those events determine the physiological consequences.

The airway collapses because during sleep, the pharyngeal dilator muscles — particularly the genioglossus, the muscle that protrudes the tongue — reduce their tone. In most people, this reduction is compensated by adequate anatomical airway diameter. In OSA patients, either the anatomy is fundamentally narrowed (by excess soft tissue, jaw position, or fat deposition around the pharynx) or the muscle compensation during the reduced-tone sleep state is insufficient to keep the airway open.

The anatomical risk factors for OSA include retrognathia (a jaw positioned too far back), micrognathia (an underdeveloped lower jaw), a high narrow palate, enlarged tonsils or adenoids, macroglossia (a relatively large tongue for the jaw size), and increased neck circumference from fat deposition around the pharynx. Nasal obstruction worsens pharyngeal collapse by creating negative pressure dynamics during inspiration. Knowing which anatomical factors are present in a given patient guides treatment selection — oral appliances, positional therapy, surgery, or CPAP each address a different piece of the anatomical picture.

What makes OSA insidious is that people often don’t know they have it. The awakening response that terminates each apnea — the brief arousal that restores pharyngeal tone and restarts breathing — is typically not remembered. Nobody experiences apneas as waking up dozens of times an hour. They experience them as unrefreshing sleep, morning headaches, daytime fatigue, difficulty concentrating, and a growing conviction that they just “aren’t a morning person.” Bed partners often notice the snoring, gasping, and witnessed apneas before the person themselves catches on.

The Cardiovascular Stakes of Untreated Sleep Apnea

Sleep apnea is not simply a sleep problem. The cardiovascular consequences of untreated moderate-to-severe OSA are among the most well-documented and serious in all of sleep medicine. Each apnea event triggers a cascade: progressive oxygen desaturation as breathing stops, hypercapnia (CO2 buildup), sympathetic nervous system activation with heart rate surge and blood pressure spike, intrathoracic pressure swings from ineffective inspiratory effort against a closed airway, and eventual arousal that restores breathing — followed by the next cycle, often 20-60 seconds later, all night long.

The cumulative hemodynamic effects of this repetitive cycle include sustained hypertension, cardiac arrhythmias (atrial fibrillation prevalence is approximately 4-fold higher in OSA patients), accelerated atherosclerosis, left ventricular hypertrophy, and increased risk of myocardial infarction and stroke. The Sleep Heart Health Study, following over 6,000 adults, found that severe OSA was associated with a 1.58-fold increased risk of coronary heart disease and a 1.97-fold increased risk of heart failure. These are not small effect sizes.

The mechanism involves several converging pathways: systemic inflammation (repeated hypoxia-reoxygenation cycles generate reactive oxygen species and trigger inflammatory cytokine production), endothelial dysfunction, oxidative stress, sympathetic nervous system overactivation, and insulin resistance. OSA independently predicts type 2 diabetes risk through its effects on glucose metabolism and cortisol dysregulation. Treating OSA effectively — by whatever method — reduces these downstream risks, which is why the choice of treatment method matters less than ensuring that actual treatment is occurring.

The brain pays a particular price. Chronic sleep fragmentation from untreated OSA impairs declarative memory consolidation (which requires slow-wave sleep), working memory, executive function, and cognitive processing speed. Chronic nocturnal hypoxia — low oxygen reaching the brain for hours every night — is increasingly recognized as a contributor to white matter hyperintensities and accelerated cognitive aging. Longitudinal data suggest that people with untreated severe OSA have significantly accelerated rates of cognitive decline, and some data links chronic untreated OSA to increased Alzheimer’s risk — potentially through impaired glymphatic clearance (the brain’s overnight “waste removal” system, dependent on slow-wave sleep).

Types of Oral Appliances

Not all oral appliances are the same. Understanding the categories helps evaluate what’s being offered and whether the treatment approach fits the anatomy and needs at hand:

Mandibular Advancement Devices (MADs): The dominant category, representing the vast majority of prescribed oral appliances. These custom-fit devices attach to both upper and lower teeth and use an adjustable mechanism that positions the lower jaw forward in calibrated increments. The forward mandibular position pulls the attached tongue base anteriorly, increasing pharyngeal cross-sectional area. Custom MADs are fabricated from dental impressions by a dentist trained in dental sleep medicine and are far superior to boil-and-bite OTC versions in fit, therapeutic range, and durability. Brands include Somnodent, Herbst, EMA, SUAD, Narval, and many others — differences are largely in mechanism design and material rather than fundamental efficacy.

Tongue Retaining Devices (TRDs): These work differently — rather than advancing the jaw, they hold the tongue forward using suction via a bulb that fits over the tongue tip. They’re appropriate for patients who can’t tolerate mandibular advancement due to temporomandibular joint problems, insufficient teeth for MAD attachment, or anatomy that doesn’t respond to jaw advancement. Less commonly prescribed and generally less comfortable, but the appropriate choice for a specific subset of patients.

Combination therapy devices: MADs can be used with positional therapy devices to prevent back-sleeping, or with CPAP in patients who need combined treatment. CPAP-plus-MAD is used in patients with severe OSA who can’t tolerate adequate CPAP pressure — the MAD reduces required CPAP pressure, improving comfort and adherence while maintaining cardiovascular protection.

OTC devices: Boil-and-bite mandibular advancement devices are available OTC and inexpensive. Research shows they modestly reduce AHI in mild OSA, but are significantly inferior to custom devices in efficacy, comfort, and durability. Associated with higher rates of tooth discomfort, jaw pain, and bite changes. Acceptable for short-term trial before committing to custom fabrication. Not appropriate for moderate-severe OSA or long-term use without professional monitoring.

The Evidence: Where Oral Appliances Compete With CPAP

1. MADs are consistently worn for more hours per night than CPAP — typically 6-7 hours versus 4-5 hours in head-to-head studies
2. Cardiovascular risk reduction (blood pressure, endothelial function) with MAD is comparable to CPAP in mild-to-moderate OSA
3. Daytime sleepiness improvement is similar between MAD and CPAP in pragmatic effectiveness trials
4. Neurocognitive outcomes are equivalent in patients with adequate AHI response to MAD
5. Patient preference favors MAD when both options are offered
6. Quality of life improvements are comparable between groups

The conventional medical hierarchy puts CPAP above oral appliances for OSA treatment — and this ranking is correct when comparing device efficacy alone. CPAP, when used, is more effective at reducing AHI across all severity levels. The critical word there is “when used.”

The landmark study that reframed the entire debate was published in the American Journal of Respiratory and Critical Care Medicine. Researchers found that while CPAP reduced AHI more effectively than MAD in laboratory conditions, blood pressure reduction — a key clinical outcome representing cardiovascular risk — was statistically equivalent between groups. The explanation was clear: MAD adherence was substantially higher. Patients wore the oral appliance for significantly more hours per night than they wore CPAP. Effective adherence multiplied by moderate efficacy produced equivalent real-world outcomes compared to poor adherence multiplied by high efficacy.

This effectiveness-versus-efficacy distinction has been confirmed repeatedly across subsequent trials and meta-analyses:

Current guidelines from the American Academy of Sleep Medicine explicitly support oral appliances as an alternative to CPAP for all severities of OSA in patients who prefer them or who are CPAP intolerant — a significant evolution from earlier guidance that reserved OAs primarily for mild OSA. The shift reflects the accumulating effectiveness data and recognition that treatment adherence is a treatment outcome in itself.

For severe OSA (AHI above 30), CPAP remains the preferred first-line treatment when tolerated, due to the larger AHI reduction and higher likelihood of persistent severe apnea with MAD alone. That said, in patients with severe OSA who genuinely cannot tolerate CPAP, MAD is far preferable to no treatment — and a proportion of severe OSA patients achieve excellent AHI control with MAD, particularly those with favorable anatomy.

“A CPAP machine sitting on your nightstand because you can’t tolerate wearing it is not treatment. It is a $2,000 anxiety device. The best sleep apnea treatment is the one you will consistently use every night, for the rest of your life.”

Getting Fitted: The Process and What to Insist On

A proper custom oral appliance involves a structured process — not just taking dental impressions and sending off an order. Knowing the expected steps helps identify underpowered care:

Step 1 — Sleep study diagnosis: An objective diagnosis is required before treatment. Home sleep testing (HST) is appropriate for most patients with suspected OSA without significant comorbidities. In-lab polysomnography (PSG) is indicated for complex cases, suspected central sleep apnea, parasomnias, or atypical presentations. A dentist fabricating an appliance without a baseline sleep study diagnosis is practicing outside the standard of care.

Step 2 — Dental evaluation: The treating dentist needs to assess tooth health and number, gum condition, jaw joint status (TMJ), maximum jaw opening, and bite relationship. This evaluation identifies any contraindications. Patients with insufficient teeth for appliance attachment, active TMJ disorder, or significant periodontal disease may be poor candidates or require treatment modification.

Step 3 — Device selection and fabrication: Digital or physical impressions are taken. A protrusive bite registration establishes the initial forward jaw position (typically 50-75% of maximum protrusion for the starting position). The device is custom fabricated in a dental laboratory — typically 2-4 weeks.

Step 4 — Fitting and titration: The delivery appointment establishes the initial jaw position — not the final therapeutic position. Titration is the critical process of gradually advancing the mandible in 0.25-0.5mm increments over 6-12 weeks until reaching the position that provides optimal AHI reduction with acceptable side effects. Many providers rush titration, delivering inadequate treatment. The titration target is driven by sleep study data — periodic home sleep tests during titration allow objective tracking of AHI improvement at each advancement position.

Step 5 — Objective outcome verification: After reaching a stable therapeutic position, effectiveness must be confirmed with a repeat sleep study with the appliance in place. Subjective improvement — feeling less sleepy, snoring less — does not reliably correlate with actual AHI normalization. Residual untreated apnea carries ongoing cardiovascular risk even in patients who feel better. Objective verification is non-negotiable. Insist on it.

Step 6 — Annual follow-up: Oral appliances require annual assessment for device integrity, advancement mechanism function, bite changes, and ongoing clinical effectiveness. Sleep apnea can worsen over time with weight gain, aging, or upper airway anatomical changes — periodic re-evaluation maintains treatment adequacy over the long term.

Side Effects and How to Manage Them

Oral appliances have real side effects. Knowing them in advance reduces the odds of abandoning effective treatment over manageable problems:

Jaw and muscle soreness: Nearly universal in the first weeks. The jaw is being held in an anterior position for 6-8 hours — the masticatory muscles and TMJ ligaments are adapting to an unfamiliar position. Morning jaw exercises upon waking (gentle opening and closing, lateral excursions, protrusion-retraction for 5 minutes) dramatically reduce and accelerate resolution of this. If pain is significant, reduce advancement 0.5mm and proceed with titration more slowly. The soreness should resolve within 4-8 weeks; persistent significant pain requires evaluation.

Tooth soreness: Brief pressure sensitivity on waking, resolving within minutes, is common and benign during initial titration. Persistent tooth pain, sensitivity to temperature, or tooth mobility requires dental evaluation — excessive force on specific teeth may need appliance adjustment.

Excessive salivation: The foreign body in the mouth stimulates salivary production. Nearly universal in the first weeks. Self-resolves with habituation in the majority of patients within 4-8 weeks.

Dry mouth: Some patients mouth-breathe around or through the device, creating morning dry mouth. Nasal obstruction (from allergy, polyps, or deviated septum) worsens this — treating concurrent nasal disease improves MAD tolerance.

Occlusal (bite) changes: This is the most clinically significant long-term side effect. After years of use, permanent changes in bite relationship — forward movement of the lower front teeth, changes in contact between upper and lower dentition — occur in a substantial proportion of long-term MAD users. Studies report measurable bite changes in 30-50% of patients after 5+ years of use. Most changes are minor and clinically insignificant; some require orthodontic correction or appliance modification. Morning occlusal repositioning exercises — 2-5 minutes of jaw exercise immediately upon removing the device — can reduce but not eliminate this risk. Annual dental monitoring with bite records allows early detection. This risk should be openly discussed before initiating treatment.

TMJ symptoms: Active temporomandibular joint disorder is a relative contraindication to MAD use. In patients with subclinical TMJ issues, the sustained forward jaw position of MAD can exacerbate clicking, pain, or joint inflammation. If significant TMJ symptoms develop, evaluation by a dentist with TMJ expertise is needed — appliance design modification, adjustment, or discontinuation may be indicated.

Who Benefits Most and Who Predicts Poor Response

Patient selection significantly affects oral appliance outcomes. The anatomy that predicts best MAD response:

1. Retrognathic or retrusive jaw position — there is room to advance the mandible into a more anatomically optimal position
2. Positional OSA — AHI predominantly worse in supine position, indicating significant anatomical compliance contributing to collapse
3. Mild-to-moderate AHI (5-30 events per hour)
4. Normal or near-normal body weight
5. Smaller neck circumference (less pharyngeal fat deposition)
6. Good dentition and jaw opening range for appliance attachment
7. No active TMJ disorder

Factors associated with poorer MAD response and need for CPAP or surgical options:

1. Severe obesity — extensive pharyngeal fat deposition limits the airway diameter that jaw advancement can achieve
2. Large neck circumference above 17 inches in men
3. Severe OSA with predominantly non-positional events
4. Significant tonsillar hypertrophy — tonsillectomy may produce better AHI reduction than MAD
5. Predominantly central sleep apnea pattern — jaw advancement does not address central events
6. Very low maximum mandibular protrusion range

Drug-induced sleep endoscopy (DISE) is an emerging diagnostic procedure that visualizes the airway during pharmacologically induced sleep, identifying the specific pattern and location of collapse. Patients whose collapse pattern is oropharyngeal and jaw-advancement-responsive predict better MAD outcomes than patients with tongue-base-dominant or multi-level collapse. DISE is not yet standard of care for oral appliance selection but is increasingly used in academic centers with complex patients.

Combining Oral Appliance Therapy With Lifestyle Modifications

Oral appliance therapy works best as part of comprehensive sleep apnea management rather than as a standalone intervention:

Weight management: This is the highest-use lifestyle intervention for OSA. Every 10% reduction in body weight reduces AHI by approximately 26% in research models. Some patients who achieve meaningful weight loss combined with MAD titration progress to normalized AHI that no longer requires treatment — though weight regain typically restores the apnea. For patients with obesity-dominant OSA, weight management is the most important long-term intervention, and GLP-1 agonists (semaglutide/tirzepatide) in the trial setting have shown remarkable AHI reductions in OSA patients with obesity — up to 50-60% AHI reduction in some trials.

Positional therapy: 50-70% of OSA patients have predominantly positional disease — AHI significantly higher when sleeping supine than in lateral positions. Positional therapy devices (vibrotactile feedback devices worn on the torso, specialized positional pillows, the classic “tennis ball sewn into the back of a shirt”) combined with MAD can improve outcomes substantially in this subgroup. A randomized controlled trial found combination positional therapy plus MAD superior to MAD alone for positional OSA. For patients with purely positional mild OSA, positional therapy alone may normalize AHI without any appliance.

Alcohol and sedative management: Alcohol reduces pharyngeal muscle tone beyond baseline sleep-related reduction and worsens OSA. Even moderate evening alcohol consumption increases AHI substantially. Eliminating evening alcohol is one of the most immediately impactful behavioral interventions for OSA. Benzodiazepines and opioids have similar airway-depressant effects. If sleeping medications are being used to compensate for poor sleep from untreated OSA, addressing the OSA eliminates the downstream need.

Myofunctional therapy: Oropharyngeal exercises — structured training of the tongue, soft palate, and pharyngeal muscles — have shown a 50% average AHI reduction in a 2015 systematic review and meta-analysis. That’s not a marginal effect. An oral myofunctional therapist teaches a targeted protocol of exercises performed daily for 15-20 minutes. For children with OSA, myofunctional therapy is particularly well-supported and can produce lasting structural changes in the developing airway. In adults, it’s a powerful adjunct that reduces appliance requirements and may improve long-term outcomes.

Nasal airway optimization: Nasal obstruction worsens OSA by creating negative inspiratory pressure that promotes pharyngeal collapse. Treating allergic rhinitis, nasal polyps, or deviated septum — with topical corticosteroids, immunotherapy, or surgical correction — improves MAD tolerance and reduces pharyngeal collapse tendency. Nasal strips and internal nasal dilators provide modest benefit by reducing nasal airway resistance during sleep.

Surgical Options for Sleep Apnea

Surgery for OSA exists along a spectrum from minor office procedures to complex skeletal reconstructions. Understanding the field helps put oral appliances in context within the overall treatment hierarchy:

Tonsillectomy and adenoidectomy: The primary surgical intervention for children with OSA due to adenotonsillar hypertrophy. Curative in the majority of pediatric cases. In adults with significantly enlarged tonsils contributing to pharyngeal narrowing, tonsillectomy produces meaningful AHI reduction but is rarely curative in isolation.

Uvulopalatopharyngoplasty (UPPP): The most commonly performed adult OSA procedure historically. Removes excess soft tissue from the palate and pharyngeal walls. Variable outcomes — 40-60% response rates in selected patients, with responses not sustained in a significant proportion over time. The failure rate has driven the field toward more anatomically targeted procedures guided by DISE-identified collapse patterns.

Hypoglossal nerve stimulation (Inspire): The most significant surgical advance in adult OSA in a generation. An implanted device delivers mild electrical stimulation to the hypoglossal nerve, activating the genioglossus and other tongue muscles during inspiration to maintain airway patency. FDA-approved for moderate-severe OSA in patients who have failed or cannot tolerate CPAP. Trial data shows sustained 50-80% AHI reduction in appropriate candidates. The selection criteria exclude patients with complete concentric palatal collapse pattern (identified on DISE) and significant obesity. It is expensive, requires surgery, and the battery requires replacement at 10-11 years — but for appropriate candidates it is a transformative treatment option.

Maxillomandibular advancement (MMA): The most effective surgical procedure for OSA — surgical repositioning of both the upper and lower jaws forward, expanding the bony pharyngeal framework permanently. Success rates of 80-95% in selected patients. Reserved for patients with significant skeletal anatomy contribution to OSA, or for those who have failed other interventions. Major procedure with significant recovery and facial appearance changes. Highly effective and worth serious consideration for appropriate anatomical candidates who have failed more conservative treatments.

Monitoring Sleep Apnea Over Time

Sleep apnea is not a static diagnosis. It changes with body weight, aging, alcohol use patterns, hormonal changes, and anatomical changes over time. A treatment that adequately controlled OSA five years ago may no longer be sufficient if these variables have changed. Building a monitoring plan into the overall sleep health strategy is essential for maintaining the cardiovascular protection that treatment is intended to provide.

For people using oral appliances, the minimum monitoring protocol should include annual dental follow-up assessing appliance condition and bite changes, and periodic repeat home sleep testing — every 1-2 years in stable patients, more frequently if symptoms change. Significant weight gain, worsening snoring, return of daytime sleepiness, or bed partner-reported increase in witnessed apneas should all trigger earlier re-evaluation rather than waiting for the next scheduled appointment.

Consumer wearable devices — the Oura Ring, Apple Watch, Withings Sleep, CPAP adherence data from connected machines — provide useful trending data that can flag clinically meaningful changes between formal sleep studies. They are not diagnostic substitutes, but they are increasingly sensitive to sleep fragmentation patterns that correlate with worsening OSA. Using this data as an early warning system that prompts formal re-evaluation is a reasonable monitoring strategy.

For CPAP users, modern machines transmit data wirelessly showing AHI, mask leak, and usage hours. Reviewing this data regularly with a sleep provider ensures treatment stays at adequate levels and that mask fit remains appropriate as the face changes over time. A residual AHI above 5 on CPAP data — even if the machine is being worn — should trigger investigation of the cause: mask leak, positional issues, or the emergence of central apneas (sometimes induced by CPAP itself, a phenomenon called treatment-emergent central sleep apnea).

FAQ About Sleep Apnea and Oral Appliances

Can I use an oral appliance if I have crowns or implants?
Often yes, but it depends on the location, number, and condition of restorations. Implants can serve as attachment points for some device designs. Crowns need to be stable. A dental sleep medicine provider needs to assess the specific situation — there is no universal answer. Significant periodontal disease with tooth mobility is a contraindication to MAD use.

How do I know if my oral appliance is actually working?
The only reliable way to confirm is objective sleep testing with the device in place at its therapeutic position. Feeling less sleepy and snoring less are encouraging signs but do not reliably confirm adequate AHI control. Residual untreated apnea — even in a patient who feels better — carries ongoing cardiovascular risk. Insist on objective verification after titration. If a provider doesn’t offer follow-up sleep testing, find one who does.

What does oral appliance therapy cost?
Custom MADs typically cost $1,800-3,500 including fitting, follow-up appointments, and adjustments. Many dental insurance plans cover a portion when medical necessity is documented through a sleep study diagnosis. Importantly, medical insurance — not just dental — may cover oral appliances under the durable medical equipment benefit. This requires the dentist to submit with proper medical billing codes to the medical insurer rather than the dental insurer. Not all providers work through this pathway, but it can dramatically reduce patient cost. Ask specifically whether medical billing will be pursued.

How long do oral appliances last?
The typical lifespan is 3-5 years depending on the degree of bruxism (teeth grinding — which accelerates appliance wear), device design, and maintenance. Most insurance policies cover replacement at 3-5 year intervals. Signs that replacement is needed include cracking, loosening of attachments, loss of retention, or malfunction of the advancement mechanism.

What about children with sleep apnea — should they use oral appliances?
Pediatric OSA management is fundamentally different from adult management. Children most commonly develop OSA from adenotonsillar hypertrophy, and adenotonsillectomy is often curative. For children with skeletal anatomy contributors to OSA — high narrow palate, class II jaw relationship — orthodontic intervention (palatal expanders, jaw repositioning appliances) can address the underlying anatomy while growth is ongoing. Adult-style MADs are not appropriate for children with primary dentition or during active jaw growth. Myofunctional therapy for children is strongly supported and can produce lasting airway changes during the developmental window.

What is the connection between sleep apnea and cognitive decline?
It is increasingly direct. Intermittent nocturnal hypoxia damages hippocampal tissue, impairing memory consolidation. Sleep fragmentation from arousal events disrupts slow-wave sleep, during which the glymphatic system clears amyloid and tau proteins from the brain — metabolic waste products accumulating in Alzheimer’s disease. Longitudinal cohort clinical data indicates that people with untreated moderate-severe OSA have accelerated rates of cognitive decline, with some data suggesting a 1.5-2 fold increase in dementia risk. Treating OSA effectively, particularly before cognitive symptoms emerge, appears to reduce this risk — meaning sleep apnea treatment isn’t just about how tired someone feels today but about preserving cognitive function for the next 20 years.

How does positional therapy work alongside an oral appliance?
Positional therapy specifically targets the subset of OSA where collapse is predominantly or exclusively supine-position dependent. Some patients have normal AHI when sleeping on their side (lateral) but severe AHI in the back position. For these patients, preventing supine sleep eliminates most of their disease. Modern positional therapy devices use vibrotactile feedback — when the device detects the patient rolling to their back, it vibrates, prompting a position change without fully waking them. Clinical data indicates 80-90% reduction in supine sleep time with these devices, and AHI normalization in purely positional OSA patients. Combined with MAD for patients with residual lateral-position events, the two interventions can normalize AHI in patients who might otherwise need CPAP. Worth raising explicitly with a sleep provider if positional OSA is suspected.

Does sleep apnea affect testosterone and hormone levels?
Yes, significantly. OSA disrupts the hormonal environment in several ways. Most testosterone is secreted during slow-wave and REM sleep — both are fragmented by OSA. Studies consistently show lower free and total testosterone in men with untreated OSA compared to controls, with improvement after CPAP treatment. In women, OSA — which is underdiagnosed in women partly because symptoms present differently (fatigue and insomnia predominate over snoring and witnessed apneas) — disrupts estrogen and progesterone secretion patterns. Growth hormone, which peaks during slow-wave sleep, is suppressed in untreated OSA. The hormonal consequences of sleep apnea contribute to the metabolic and body composition changes common in OSA patients, creating a reinforcing cycle where OSA worsens body composition (more pharyngeal fat, lower muscle mass) which worsens OSA. Treating OSA breaks this cycle.

I use CPAP but I can’t tolerate it. What are my options?
First, the specific intolerance should be identified — mask leaks, pressure discomfort, claustrophobia, dry mouth, aerophagia, or simply feeling unable to fall asleep with the device. Many intolerances are addressable with equipment modifications: different mask designs, pressure relief modes (EPR, C-Flex), auto-titrating CPAP replacing fixed-pressure CPAP, humidification, or chin straps for mouth breathing. If these are addressed and CPAP remains genuinely intolerable, oral appliance therapy is a completely appropriate alternative — not a consolation prize but a guideline-supported primary treatment. For severe OSA patients who cannot tolerate any PAP therapy, hypoglossal nerve stimulation should be considered if anatomy is appropriate.

The overarching message here is straightforward: sleep apnea is a serious medical disease with serious consequences, and treating it — by whatever method actually gets sustained — is one of the highest-use health decisions available. The tools have never been better. Oral appliances have become sophisticated, titratable, and evidence-backed. Hypoglossal nerve stimulation has expanded surgical options for the CPAP-intolerant. GLP-1 medications are producing AHI reductions in obese patients that would have seemed implausible a decade ago. Myofunctional therapy is being rediscovered as a powerful adjunct. And the combination of positional therapy, MAD, weight management, and nasal airway optimization can normalize AHI in patients who might have been told CPAP was their only option.

What hasn’t changed is the disease biology. Every night of untreated moderate-to-severe OSA produces cardiovascular stress, inflammatory signaling, and neural consequences that accumulate over years. The urgency of treatment isn’t about how tired someone feels today — it’s about the cardiac, metabolic, and cognitive trajectory they’re on. Get a proper diagnosis. Explore all available treatment options. Use whatever treatment will actually get worn. And monitor it over time, because OSA management is a long-term commitment, not a one-time prescription.

The Practical Framework: Applying Airway Collapses During Sleep In Real Life

References

• NHLBI Sleep Health

Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map